Rhenman & Partners Asset Management AB Invests $1.31 Million in Stevanato Group S.p.A. $STVN

Rhenman & Partners Asset Management AB bought a new stake in Stevanato Group S.p.A. (NYSE:STVN) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 51,000 shares of the company’s stock, valued at approximately $1,313,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Artisan Partners Limited Partnership raised its position in Stevanato Group by 20.0% during the 2nd quarter. Artisan Partners Limited Partnership now owns 2,733,782 shares of the company’s stock worth $66,786,000 after buying an additional 455,323 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Stevanato Group by 7.1% in the third quarter. Thrivent Financial for Lutherans now owns 2,372,390 shares of the company’s stock worth $61,089,000 after acquiring an additional 156,733 shares during the period. Bamco Inc. NY raised its holdings in shares of Stevanato Group by 2.1% during the second quarter. Bamco Inc. NY now owns 1,888,050 shares of the company’s stock worth $46,125,000 after purchasing an additional 39,528 shares during the last quarter. Ranger Investment Management L.P. lifted its position in Stevanato Group by 125.6% during the second quarter. Ranger Investment Management L.P. now owns 1,321,030 shares of the company’s stock valued at $32,273,000 after purchasing an additional 735,417 shares during the period. Finally, Champlain Investment Partners LLC lifted its position in Stevanato Group by 68.7% during the second quarter. Champlain Investment Partners LLC now owns 1,300,799 shares of the company’s stock valued at $31,779,000 after purchasing an additional 529,950 shares during the period.

Trending Headlines about Stevanato Group

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Q4 beats and revenue momentum — Stevanato reported Q4 results that beat expectations (reported EPS ~$0.2114 vs. ~$0.20 consensus) and highlighted strong revenue growth, reinforcing demand for its pharmaceutical packaging and high‑value solutions. STVN Q4 Highlights
• Positive Sentiment: 2026 guidance and HVS mix — Management outlined a 2026 revenue target up to €1.308B and expects high‑value solutions (HVS) to reach ~48% of sales, supporting margin expansion potential as capex is mainly HVS‑directed. 2026 Revenue Target Article
• Positive Sentiment: Analyst buy support — At least one note (Seeking Alpha piece) reiterates a Buy thesis citing Q4/FY25 strength and long‑term demand drivers, framing current weakness as cyclical in the Engineering segment. Stevanato: Strong Q4 Results Reinforce Long-Term Growth Story
• Neutral Sentiment: Earnings call detail — Full Q4/FY25 earnings call transcripts and summaries are available for deeper read; they provide management color on capex allocation (heavy toward HVS) and the cyclical pressure in Engineering. Useful for modeling near‑term margin recovery timing. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Transcripts published — Full call transcripts (Seeking Alpha / InsiderMonkey) confirm the beat and provide verbatim management commentary for investors building scenarios. Earnings Call Transcript
• Negative Sentiment: Multiple analyst price‑target cuts — Morgan Stanley cut its PT to $19 and moved to Equal Weight; Citigroup lowered its PT to $26 (maintained Buy); KeyCorp trimmed its PT to $32 (keeps Overweight). Those revisions reduce near‑term upside expectations and likely contributed to selling pressure. Analyst PT Changes (Benzinga) KeyBanc / StreetInsider

Stevanato Group Stock Performance

NYSE:STVN opened at €15.46 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.30 and a current ratio of 1.76. The stock has a market capitalization of $4.68 billion, a PE ratio of 26.66, a P/E/G ratio of 1.42 and a beta of 0.57. Stevanato Group S.p.A. has a fifty-two week low of €13.91 and a fifty-two week high of €28.00. The company has a fifty day moving average of €17.58 and a two-hundred day moving average of €21.65.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. KeyCorp lowered their target price on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday. Citigroup dropped their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of Stevanato Group in a research report on Monday, December 29th. Finally, Jefferies Financial Group set a $17.50 price target on Stevanato Group in a report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Stevanato Group Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.